Defective processing of the transforming growth factor-β1 in azoxymethane-induced mouse colon tumors

Molecular Carcinogenesis

Volumn 37, Issue 1, 2003, Pages 51-59

  Guda, Kishore ^a   Claffey, Kevin P ^a   Dong, Mei ^a   Nambiar, Prashant R ^a   Rosenberg, Daniel W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Azoxymethane; Colon; Microarray; Plasmin; TGF 1; Tumorigenesis

Indexed keywords

AZOXYMETHANE; COMPLEMENTARY DNA; MESSENGER RNA; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; SODIUM CHLORIDE; SOMATOMEDIN B RECEPTOR; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; MALE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; AZO COMPOUNDS; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION; MALE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, IGF TYPE 2; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; URINARY PLASMINOGEN ACTIVATOR;

RICKETTSIA SP. PAR;

EID: 0038076234     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10120     Document Type: Article

References (24)

1. Massague J, Blain SW, Lo RS. TGF beta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295- 309.
2. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.
3. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990;110(4):1361-1367.
4. Taipale J, Saharinen J, Keski-Oja J. Extracellular matrix-associated transforming growth factor-beta: Role in cancer cell growth and invasion. Adv Cancer Res 1998;75:87-134.
5. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93(7):1159-1170.
6. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 1991;88(2):580-584.
7. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999;10(4):303-360.
8. Shamsuddin AK, Trump BF. Colon epithelium. II. In vivo studies of colon carcinogenesis. Light microscopic, histochemical, and ultrastructural studies of histogenesis of azoxymethane-induced colon carcinomas in Fischer 344 rats. J Natl Cancer Inst 1981;66(2):389-401.
9. Druckery E. Organ-specific carcinogenesis in the digestive tract. In: Nakahara W, Takyama S, Sugimara T, Odashima S, editors. Topics in chemical carcinogenesis. Baltimore MD: University Park Press; 1972. pp 73-101.
10. Papanikolaou A, Wang Q-S, Delker DA, Rosenberg DW. Azoxymethane-induced tumor and aberrant crypt foci in mice of different tumor susceptibility. Cancer Lett 1998;130:29-34.
11. Delker DA, Wang Q-S, Papanikolaou A, Whiteley HE, Rosenberg DW. Quantitative assessment of azoxymethane-induced aberrant crypt foci in inbred mice. Exp Mol Pathol 1999;65:141-149.
12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
13. Wang Q-S, Papanikolaou A, Sabourin CLK, Rosenberg DW. Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis. Carcinogenesis 1998;19:2001-2006.
14. Bolt AB, Papanikolaou A, Delker DA, Wang QS, Rosenberg DW. Azoxymethane induces Ki-ras activation in the tumor resistant AKR/J mouse colon. Mol Carcinog 2000;27:210-218.
15. Guda K, Giardina C, Nambiar P, Cui H, Rosenberg DW. Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumor. Mol Carcinog 2001;31(4):204-213.
16. Kojima S, Rifkin DB. Mechanism of retinoid-induced activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Physiol 1993;155(2):323-332.
17. Yang JN, Allan EH, Anderson GI, Martin TJ, Minkin CJ. Plasminogen activator system in osteoclasts. Bone Miner Res 1997;12(5):761-768.
18. Nambiar PR, Giardina C, Guda K, Aizu W, Raja R, Rosenberg DW. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res 2002;62(13):3667-3674.
19. Wang S, Souza RF, Kong D, et al. Deficient transforming growth factor-beta1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res 1997;57(13):2543-2546.
20. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72(1):1-22.
21. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001;276(20):17058-17062.
22. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342(18):1350-1358.
23. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370(6489):460-462.
24. Fitzpatrick TE, Graham CH. Stimulation of plasminogen activator inhibitor-1 expression in immortalized human trophoblast cells cultured under low levels of oxygen. Exp Cell Res 1998;245(1):155-162.